Drugs / HCR040
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04289194 | Dec 2019 → Aug 2021 | acute respiratory distress syndrome | Histocell, S.L. | Completed | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2020-12-17 | Histocell, S.L. | Histocell finaliza con éxito la primera fase del ensayo clínico del medicamento celular HC016 para tratar el distrés respiratorio causado por la covid-19 histocell.com ↗ |
| 2020-04-06 | Histocell, S.L. | Histocell inicia un ensayo clínico con su medicamento HC016 en pacientes con SDRA por covid-19 histocell.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HCR040 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04289194 ↗ |
| Known as | HC016 | “HCR040 is an investigational medicinal product whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and pulsed with H2O2.” NCT04289194 ↗ |
| Route | Intravenous | “Treatment is administered by intravenous injection.” NCT04289194 ↗ |